Purchase this article with an account.
J. Chen, H. Guo, G. Cynkowska, T. Cynkowski, P. Ashton; Sustained Release Celecoxib From Bioerodible Intraocular Devices. Invest. Ophthalmol. Vis. Sci. 2009;50(13):4993.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the release properties of two different bioerodible Celecoxib devices, which could be potentially used to treat age-related macular degeneration, diabetc retinophathy and post cataract inflammation.
Two types of sustained release devices were prepared. Device A was composed of a central core of Celecoxib in a bioerodible polermer matrix that was futher coated with a bioerodible poermer and heat cured. The devices were 0.9 mm in diameter and are disigned to be implantable. Device B was an in situ gelling system composed of Celecoxib and a bioerodible polymer in a biocompatible solvent (N-methyl-2-pyrrolidone). These systems are designed to be injectable through a 30 or 25 gauge needle. Release into phosphate buffer (pH 7.4) at 37oC was measured over one month, buffer was regularly changed. Release rates were calculated from the culmulative release (determinbed by HPLC) versus time.
Release from Device A gave a fast release of 2µg/day for the first week, followed by a steady state release of approximately 1 µg/day. Device B provided a immediate release of 10µg, followed by a steady state release of approximately 2.5 µg/day.
Both Device A and Device B provide long term constant release of Celecoxib. Initial data indicates a duration of over 6 months is possible. A key advantage of Device B may be its easiser administration (injectable via 30 gauge needle).
This PDF is available to Subscribers Only